Table 1.
UK | Italy | France | Germany | Spain | |
Market share % | |||||
pMDIs | 69.6 | 37.3 | 52.2 | 42.6 | 44.9 |
DPI/SMIs | 30.4 | 62.7 | 47.8 | 57.4 | 55.1 |
Whole market | |||||
CO2e emissions, kilo tons | 1 300 | 190 | 520 | 450 | 330 |
From pMDIs, kilo tons (%) | 1 200 (98.4) | 170 (93.7) | 500 (96.6) | 430 (94.7) | 320 (95.8) |
From DPI/SMIs, kilo tons (%) | 20 (1.6) | 12 (6.3) | 18 (3.4) | 24 (5.3) | 14 (4.2) |
Of which SABA | |||||
CO2e emissions, kilo tons | 870 | 98 | 370 | 300 | 220 |
From pMDIs, kilo tons (%) | 870 (99.9) | 97 (99.2) | 370 (99.98) | 300 (99.9) | 220 (99.7) |
From DPI/SMIs, kilo tons (%) | 1.3 (0.1) | 0.76 (0.8) | 0.058 (0.02) | 190 (0.1) | 580 (0.3) |
Whole market without SABA | |||||
CO2e emissions, kilo tons | 380 | 88 | 150 | 160 | 110 |
From pMDIs, kilo tons (%) | 370 (95.2) | 77 (87.5) | 130 (87.9) | 130 (84.7) | 95 (87.8) |
From DPI/SMIs, kilo tons (%) | 18 (4.8) | 11 (12.5) | 18 (12.1) | 24 (15.3) | 13 (12.2) |
Market share is based on the number of packs sold in 2019 in the five reference markets.
CO2e, carbon dioxide equivalent; DPI, dry-powder inhaler; pMDI, pressurised metered-dose inhaler; SABA, short-acting β2-agonist; SMI, soft mist inhaler.